Eli Lilly and Co.

Lilly, partner find no Bydureon effect on heart rhythm

June 27, 2011
Bloomberg News
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
More

Lilly diabetes pill recommended for EU approval

June 24, 2011
Bloomberg News
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
More

Lilly CEO: Immigration, tax laws slow innovation

June 23, 2011
Bloomberg News
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
More

EU approves Lilly's weekly diabetes drug Bydureon

June 21, 2011
Associated Press
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday.
More

Lilly enters collaboration deal with Swiss company

June 9, 2011
Associated Press
Drugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop other potential orthopedic treatments.
More

Lilly wins ruling in dispute with Amylin over diabetes drugs

June 8, 2011
Bloomberg News
Eli Lilly and Co. won a ruling in a lawsuit brought by Amylin Pharmaceuticals Inc., which wants to prevent Lilly from using the same people to sell Amylin’s diabetes drug and that of a competitor.
More

Drug industry outlook negative through 2012, Moody’s says

June 8, 2011
Bloomberg News
Earnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
More

Roche wins as high court limits university patent rights

June 6, 2011
Bloomberg News
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
More

Lilly licenses Xigris rights to new biotech firm

May 23, 2011
J.K. Wall
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
More

Growth in drug spending to slow as generics rise

May 18, 2011
Bloomberg News
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
More

Amylin sues Lilly over drug development deal

May 16, 2011
Associated Press
Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.
More

Eli Lilly's slumbering stock finally shows signs of lifeRestricted Content

May 14, 2011
Greg Andrews
Is it finally time to get some growth again out of a stock that since its debut on the public market 59 years ago has minted thousands of millionaires?
More

Lilly drug to detect Alzheimer’s criticized by consumer group

May 11, 2011
Bloomberg News
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
More

Two wins to bring Lilly modest sales

May 9, 2011
J.K. Wall
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
More

Eli Lilly pledges $2.5 million to Mind Trust

May 5, 2011
J.K. Wall
Eli Lilly and Co. plans to give $2.5 million toward a new fundraising campaign by the Mind Trust, an Indianapolis-based education reform group.
More

FDA OKs new diabetes pill from Lilly, Boehringer

May 2, 2011
 IBJ Staff and Associated Press
The Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients who can't control their blood sugar with older medicines.
More

Lilly teams with Medtronic on Parkinson's treatment

April 26, 2011
J.K. Wall
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
More

Lilly shareholders fail to remove anti-takeover measures

April 18, 2011
J.K. Wall
A proposal that would have weakened Eli Lilly and Co.’s defenses against an unwanted takeover failed to pass Monday despite a large majority of shareholders voting to remove those barriers for the second straight year.
More

Analysts demand news on next Lilly blockbuster

April 18, 2011
J.K. Wall
Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.
More

Lilly shares falter after quarterly earnings report

April 18, 2011
J.K. Wall
Eli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped anyway Monday morning, along with the broader market.
More

Charges drive down first-quarter profit at Lilly

April 18, 2011
J.K. Wall
First-quarter profit fell at Eli Lilly and Co. as the company recorded restructuring charges due to its downsizing and higher research costs as it tries to develop new drugs to help it shrug off its looming patent expirations.
More

FDA wants further testing of Lilly pancreas drug

April 16, 2011
Associated Press
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
More

Lilly’s Bydureon wins backing of European drug panel

April 15, 2011
Bloomberg News
The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
More

Six faces behind Indianapolis business Twitter handles

April 9, 2011
Gabrielle Poshadlo
Meet the people who tweet for Indianapolis Symphony Orchestra, AAA, Butler University and other local businesses.
More

China making big gains in drug R&D jobs state covets

April 9, 2011
Greg Andrews
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT